Adding Polivy to Standard of Care Boosts Survival in Relapsed/Refractory DLBCL

By News Health
8 hours Ago

(MedPage Today) — Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the phase III POLARGO trial showed…

Source link : https://www.medpagetoday.com/meetingcoverage/eha/116098

Author :

Publish date : 2025-06-16 19:39:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Telehealth Geriatric Cancer Assessment Passes Phase III Test in Low-Resource Setting

Removed ACIP Members Say 'U.S. Vaccine Program Critically Weakened'

The prospectors hunting hydrogen along a US continental rift

Second Patient Dies After Gene Therapy for Duchenne Muscular Dystrophy

VA Disputes Story Asserting That New Rules Allow Docs to Discriminate

The Milky Way's black hole may be spinning at top speed